Mode
Text Size
Log in / Sign up
N/A Completed N=31 Treatment

Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME II)

Source: ClinicalTrials.gov NCT03847233 ↗
Enrolled (actual)
31
Serious AEs
9.7%
Results posted
Dec 2020
Primary outcomePrimary: Number of Patients With Lesion Success — 22 Participants

Summary

The purpose of this study is to evaluate the safety and effectiveness of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in native superficial femoral artery (SFA) and/ or proximal popliteal arteries (PPA).

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Lesion Success
22

Eligibility Criteria

Inclusion Criteria

  • Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2-4
  • Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA of which meet the following criteria:
  • Severely calcified lesions with degree of stenosis ≥70%
  • Vessel diameter ≥3.0 mm and ≤6.0 mm
  • Total lesion length (or series of lesions) ≤150 mm

Exclusion Criteria

  • Target lesion/vessel with in-stent restenosis
  • History of major amputation in the target limb
  • Subject has a history of coagulopathy or hypercoagulable bleeding disorder
  • Subject with untreatable hemorrhagic disease or platelet count 600,000mm3 as baseline assessment.
  • History of myocardial infarction, or stroke/cerebrovascular accident (CVA) within 6 months prior to study enrollment
  • Unstable angina pectoris at the time of the enrollment
  • Septicemia at the time of enrollment
  • Presence of other hemodynamically significant outflow lesions in the target limb requiring a planned surgical intervention or endovascular procedure within 30 days after the index procedure
  • Presence of aneurysm in the target vessel
  • Acute ischemia and/or acute thrombosis of the SFA/PPA prior to the index procedure
  • Perforated vessel as evidenced by extravasation of contrast media prior to the index procedure
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03847233). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search